Shenzhen Shankang Pharmaceutical Technology Co., Ltd. is mainly engaged in the research and development, production, and sales of addiction treatment drugs represented by the treatment of opioid/new drug relapse and alcohol use disorders. It is an innovative drug research and development enterprise with international independent intellectual property rights and a global perspective, committed to creating a "Chinese solution" for addiction treatment.

     Since its establishment, the company has been committed to solving the global problem of addiction to psychoactive substances. Through years of research and development innovation accumulation, the company has formed a drug delivery system technology platform centered on long-acting slow-release implant technology, and focuses on innovative applications in addiction treatment, central nervous system disease treatment, and other disease fields, forming multiple core research and development pipelines.

    Among them, SK2007 is the world's first ultra long acting abstinence medication that lasts up to 5 months. A single implantation of the medication can effectively reduce alcohol consumption. It has completed Phase II clinical trials and is currently undergoing Phase III clinical trials.

    SK1808 is a registered opioid anti relapse indication product of naltrexone hydrochloride implant in the United States, which complies with FDA regulatory requirements. In 2025, it was granted implied permission by the FDA to conduct Phase I clinical trials in the United States.

    SK1908 implant is used for anti relapse treatment of new drugs such as methamphetamine, and is also the world's first drug used for preventing relapse of marijuana addiction. It can be released for 3 months after one implantation and is about to be declared for IND.

    SK2110 implant, the first long-acting formulation for treating severe depression,The IND application is about to be submitted.

    SK2105 implant, prevention of relapse in patients with strong addiction to fentanyl drugs, and treatment of alcohol use disorders,The IND application is about to be submitted.

    SK2109 implant, the world's first long-acting smoking cessation implant, with a continuous release of the drug for 3 months after implantation.